AstraZeneca wins early U.S. approval for blood cancer drug

LONDON (Reuters) – AstraZeneca has won U.S. approval for a new blood cancer drug several months earlier than expected, boosting its oncology portfolio – and requiring it to pay $1.5 billion to shareholders in the biotech company that first discovered the medicine.

Source: Reuters Health News